BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Neuroendocrine tumors clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for neuroendocrine tumors: 339 (209 sponsors; 29 newly posted in the last 180 days, 17 stopped in the last 180 days; 12 new-entrant sponsors). Momentum score 8.8, rank 79 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 97, Phase 2 141, Phase 3 52, Phase 4 5, N/A 42.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Bristol-Myers Squibb BMY9P2 3, NA 2, P3 3, P4 101
Merck Sharp & Dohme LLC MRK9P2 6, P3 301
Regeneron Pharmaceuticals REGN7P3 3, P2 412
IDEAYA Biosciences IDYA6P2 3, P3 313
Biocad3P3 301
Suzhou Zelgen Biopharmaceuticals Co.,Ltd8P2 6, P3 212
Exelixis EXEL4P3 2, P4 1, P1 120
ITM Solucin GmbH3P3 2, P1 100
Philogen S.p.A.3P2 1, P3 200
Boehringer Ingelheim9P2 2, P1 6, P3 111
Novartis Pharmaceuticals NVS9P2 2, NA 2, P1 3, P3 1, P4 111
Replimune, Inc. REPL5P2 2, NA 1, P1 1, P3 100
Aura Biosciences AURA4P3 1, NA 300
Iovance Biotherapeutics, Inc. IOVA4P2 3, P3 100
Pfizer PFE4P3 1, P1 300
Advanced Accelerator Applications3P2 1, P3 1, NA 100
Immatics US, Inc. IMTX3P2 1, P1 1, P3 100
Amgen AMGN2P3 1, P2 100
Binhui Biopharmaceutical Co., Ltd.2P2 1, P3 100
Crinetics Pharmaceuticals Inc.2P2 1, P3 100
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2P3 1, P2 100
Erasca, Inc. ERAS2P3 1, P1 100
IO Biotech2P3 1, P2 100
Linnaeus Therapeutics, Inc.2P3 1, P2 100
Pierre Fabre Medicament2P3 1, P1 101

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3RayzeBio, Inc.NCT05477576 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyGEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Diactive not recruiting343
2026-12 est.P1/P2Monte Rosa Therapeutics, Inc GLUENCT05546268 Study of Oral MRT-2359 in Selected Cancer PatientsNSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC active not recruiting174
2026-12 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05884255 An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Advanced Gastroenteropancreatic Neuroendocrine Tumorrecruiting220
2026-12-28 est.P1/P2Nanjing Leads Biolabs Co.,LtdNCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaAdvanced Neuroendocrine Carcinomarecruiting178
2026-12-31 est.P1/P2Chimeric TherapeuticsNCT06055439 A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell TherapyNeuroendocrine Tumors; Colorectal Cancer; Gastric Canceractive not recruiting135
2027-01-01 est.P2Biotheus Inc.NCT05879055 A Study of PM8002 in Combination With Chemotherapy in Patients With NENNeuroendocrine Neoplasmactive not recruiting31

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Camurus ABNCT05050942 A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETGastro-enteropancreatic Neuroendocrine Tumoractive not recruiting332
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-09 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05978284 Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaSmall Cell Lung Cancer; Neuroendocrine Carcinomarecruiting54
2026-07 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06372626 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.Neuroendocrine Carcinomaunknown93

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "neuroendocrine tumors"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.